lymphoma

Documents about lymphoma

• Pralatrexate + Romidepsin in Relapsed/Refractory Lymphoid Malignancies#802647ClinicalTrials.gov
• Sample Collection for Ongoing Research and Product Evaluation Study - Non-Hodgkin Lymphoma (SCORE-NHL)#827673ClinicalTrials.gov
• Haploidentical BMT With Post-Transplant Cyclophosphamide and Bendamustine#832267ClinicalTrials.gov
• Monoclonal Antibody Therapy in Treating Patients With Recurrent or Refractory Lymphoma#803492ClinicalTrials.gov
• Dendritic Cell Therapy, Cryosurgery, and Pembrolizumab in Treating Patients With Non-Hodgkin Lymphoma#812433ClinicalTrials.gov
• Autologous Stem Cell Transplant Followed by Polatuzumab Vedotin in Patients With B-cell Non-Hodgkin and Hodgkin Lymphoma#805653ClinicalTrials.gov
• Immunotherapy in Lymphoma#152424ClinicalTrials.gov
• Irinotecan in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma#801343ClinicalTrials.gov
• Rituximab in Treating Patients With Follicular Non-Hodgkin's Lymphoma#834927ClinicalTrials.gov
• CRISPR-Edited Allogeneic Anti-CD19 CAR-T Cell Therapy for Relapsed/Refractory B Cell Non-Hodgkin Lymphoma (ANTLER)#837738ClinicalTrials.gov
• AutologousCD22 Chimeric Antigen Receptor (CAR)T Cells in w/Recurrent/Refractory B Cell Lymphomas#810294ClinicalTrials.gov
• A Study of Brentuximab Vedotin in Relapsed or Refractory Non-Hodgkin Lymphoma#238097ClinicalTrials.gov
• Amping up With PemJAK#249578ClinicalTrials.gov
• R-MACLO-IVAM and Thalidomide in Untreated Mantle Cell Lymphoma#832825ClinicalTrials.gov
• Follicular Lymphoma IV/SC Rituximab Therapy (FLIRT)#405168ClinicalTrials.gov
• Primary Rituximab and Maintenance#836387ClinicalTrials.gov
• Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells#181761ClinicalTrials.gov
• Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy#838264ClinicalTrials.gov
• A Phase I/II Trial of VR-CHOP in Lymphoma Patients#838664ClinicalTrials.gov
• Ibrutinib in Treating Patients With Refractory or Relapsed Lymphoma After Donor Stem Cell Transplant#840174ClinicalTrials.gov
• Rituximab Plus Lenalidomide for Patients With Relapsed / Refractory Indolent Non-Hodgkin's Lymphoma (Follicular Lymphoma and Marginal Zone Lymphoma)#353262ClinicalTrials.gov
• Diagnostic Study of Patients With Aggressive Non-Hodgkin's Lymphoma#810877ClinicalTrials.gov
• Lenalidomide With or Without Rituximab in Treating Patients With Progressive or Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Prolymphocytic Leukemia, or Non-Hodgkin Lymphoma Previously Treated With Donor Stem Cell Transplant#830441ClinicalTrials.gov
• A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL)#804998ClinicalTrials.gov
• Acalabrutinib and Obinutuzumab for the Treatment of Previously Untreated Follicular Lymphoma or Other Indolent Non-Hodgkin Lymphomas#180408ClinicalTrials.gov
• Study of ADCT-402 in Patients With Relapsed or Refractory B-cell Lineage Non Hodgkin Lymphoma (B-NHL)#829307ClinicalTrials.gov
• VEGF Trap in Treating Patients With Relapsed or Refractory Solid Tumors or Non-Hodgkin's Lymphoma#811953ClinicalTrials.gov
• Chemoradiotherapy With Targeted Immunotherapy in Pediatric Lymphoma#474754ClinicalTrials.gov
• Molecular and Cellular Characterization of MALT Lymphoma#837300ClinicalTrials.gov
• Safety Study of XmAb®2513 to Treat Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma#810311ClinicalTrials.gov
• Monoclonal Antibody Therapy in Treating Patients With Refractory Anaplastic Large Cell Lymphoma or Hodgkin's Lymphoma#827794ClinicalTrials.gov
• Copanlisib and Nivolumab in Treating Patients With Richter's Transformation or Transformed Indolent Non-Hodgkin Lymphoma#429764ClinicalTrials.gov
• AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma#826426ClinicalTrials.gov
• Testing the Combination of Nivolumab and ASTX727 for Relapsed or Refractory B-Cell Lymphoma#454010ClinicalTrials.gov
• A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies#829034ClinicalTrials.gov
• Acalabrutinib and Anti-CD19 CAR T-cell Therapy for the Treatment of B-cell Lymphoma#474745ClinicalTrials.gov
• Ofatumumab in Treating Patients With Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma#828987ClinicalTrials.gov
• Peripheral Stem Cell Transplantation Plus Combination Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Non-Hodgkin's Lymphoma#811717ClinicalTrials.gov
• Pembrolizumab With Rituximab or Obinutuzumab in Treating Patients With Relapsed or Refractory Follicular Lymphoma or Diffuse Large B Cell Lymphoma#300266ClinicalTrials.gov
• Combination Chemotherapy Plus Interferon Alfa or Rituximab in Treating Patients With Stage III or Stage IV Lymphoma#810357ClinicalTrials.gov
• Romidepsin, Ifosfamide, Carboplatin, and Etoposide in Treating Participants With Relapsed or Refractory Peripheral T-Cell Lymphoma#826383ClinicalTrials.gov
• Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy#201757ClinicalTrials.gov
• Mosunetuzumab and Polatuzumab Vedotin for Untreated Follicular Lymphoma#369826ClinicalTrials.gov
• Double Cord Versus Haploidentical (BMT CTN 1101)#833657ClinicalTrials.gov
• SWOG-9320 Combination Chemotherapy, Radiation Therapy, and Antiviral Therapy in Treating Patients With AIDS-Related Lymphoma#812927ClinicalTrials.gov
• Ibrutinib and Venetoclax in Relapsed and Refractory Follicular Lymphoma#827412ClinicalTrials.gov
• Study of Pembrolizumab With Chemotherapy in Patients With Advanced Lymphoma (PembroHeme)#838817ClinicalTrials.gov
• Obinutuzumab With or Without Umbralisib, Lenalidomide, or Combination Chemotherapy in Treating Patients With Relapsed or Refractory Grade I-IIIa Follicular Lymphoma#217030ClinicalTrials.gov
• CD19.20.22 CAR T-cells for Patients With Relapsed/Refractory B-Cell Lymphomas#349945ClinicalTrials.gov
• Pembrolizumab and Vorinostat in Patients With Relapsed or Refractory DLBCL, FCL or HL.#836952ClinicalTrials.gov

Related topics